Sodium butyrate / tributyrin
Sodium Butyrate / Tributyrin · also known as Butyrate, Tributyrin, Postbiotic Butyrate
Butyrate is an important energy source for colonic epithelial cells. In animal models it can regulate tight junction proteins, and in experimental studies it can also inhibit HDAC and promote the differentiation of some regulatory T cells. It is not yet clear whether standard oral products reach effective concentrations in the human colon.
Clinical uses and human evidence
Irritable bowel syndrome
Studies (2)
- Banasiewicz 2013 · Colorectal Dis · RCT · n=66 — Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome
- Panufnik 2026 · Sci Rep · RCT · n=52 — Effect of microencapsulated sodium butyrate on abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes: a randomized placebo-controlled trial
Diarrhea (including antibiotic-associated diarrhea)
Blood sugar and insulin resistance
Studies (2)
- Panufnik 2026 · Sci Rep · RCT · n=52 — Effect of microencapsulated sodium butyrate on abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes: a randomized placebo-controlled trial
- Testa 2026 · Clin Nutr · RCT · n=46 — Targeting weight loss and blood glucose control with oral sodium butyrate in overweight/obese adults with and without type 2 diabetes: A proof-of-concept randomized controlled trial
Body weight and body fat
Mechanisms of action
Epithelial tight junction (ZO-1 / Occludin) reinforcement and barrier repair
Butyrate is an important fuel for colonic epithelial cells. In animal models, including mice with scald burns, it can reduce the rise in intestinal permeability and the tight junction protein abnormalities. How much of a standard oral product reaches the human colon, and how ZO-1 and Occludin respond in humans, has not been established.
References (2)
- Liang et al. 2020 · Study in mice with scald burns: sodium butyrate reduced increased intestinal permeability and abnormal tight junction proteins
- Tabat et al. 2020 · Ex vivo human colon tissue experiment: butyrate effects varied with experimental conditions and cannot be equated with the results of oral treatment
Epigenetic inhibition of histone deacetylases (HDACs)
In some experimental models, butyrate can inhibit HDAC and promote the differentiation of some regulatory T cells. The evidence for HDAC inhibition and Foxp3-related acetylation comes from animal and in-vitro studies. Whether standard oral products reach effective concentrations in target human tissues is still uncertain.
References (2)
- Furusawa et al. 2013 · Mouse and cell experiments: butyrate promoted the differentiation of colonic regulatory T cells and affected histone acetylation at the Foxp3 locus
- Edelman et al. 2003 · Human pharmacokinetic study: examined butyrate exposure from tributyrin at doses far higher than typical supplement doses
Colonic short-chain fatty acid (SCFA/butyrate) fermentation substrate and receptor activation
Exogenous butyrate can serve as a fuel for the epithelium. Animal studies suggest its protective effect on the intestinal mucosa is linked to GPR109A. There is no direct evidence that standard oral products activate GPR41 and GPR43 in the human colon, and the effect also depends on the product.